About Contact Us Careers
Sign In

Cardiovascular Clinical Trials Market - Top Companies and Manufacturers

  • Report ID: 6125
  • Published Date: Jun 06, 2024
  • Report Format: PDF, PPT

Companies Dominating the Cardiovascular Clinical Trials Landscape

    Furthermore, industries playing vital role in providing clinical trials of cardiovascular facilitating advanced technologies and AI integration to execute smooth and accurate process. Key players dominating cardiovascular clinical trials market include:

    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • Bayer AG
    • AstraZeneca
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH.
    • Edwards Lifesciences Corporation.
    • Siemens Healthineers AG
Browse Key Market Insights with Data Illustration:

In the News

  • Pfizer Inc. announced that its board of directors had declared a dividend of $0.42 in the second quarter of 2024 of the company’s common stock, payable on June 14, 2024, to holders of Common Stock of record at work expires on May 10, 2024. The 2024 second quarter cash dividend will be the 342nd consecutive quarterly dividend payment by Pfizer.
  • AstraZeneca announced the successful completion of an investment in Cellectis, a clinical biotechnology company. The joint investment and research agreement, announced in November 2023, will utilize Cellectis proprietary gene editing technology and design capabilities, to develop up to 10 new cell and gene therapy products for the areas of great unmet need, including oncology, immunology, and rare diseases.

Author Credits:  Radhika Pawar


  • Report ID: 6125
  • Published Date: Jun 06, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of cardiovascular clinical trials was over USD 5. billion.

The market size for Cardiovascular Clinical Trials is projected to cross USD 11.70 billion by the end of 2036 expanding at a CAGR of 6% during the forecast period i.e., between 2024-2036.

The major players in the market are AstraZeneca, AbbVie Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, and others.

The interventional segment is anticipated to garner a share/size of 48% during 2024-2036.

The North America cardiovascular clinical trials sector is poised to hold 34% share by the end of 2036.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample